Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy

UnknownOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

December 30, 2023

Study Completion Date

January 30, 2024

Conditions
Coronary Allograft Vasculopathy (CAV)
Interventions
DEVICE

CardioFlux

CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.

Trial Locations (1)

44195

RECRUITING

The Cleveland Clinic, Cleveland

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

lead

Genetesis Inc.

INDUSTRY

NCT05751915 - Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy | Biotech Hunter | Biotech Hunter